2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1144A
    Oxyntomodulin (bovine, porcine) TFA 98%
    Oxyntomodulin (bovine, porcine) TFA, a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist.
    Oxyntomodulin (bovine, porcine) TFA
  • HY-P11463
    Des-threoninol-octreotide 160841-00-9
    Des-threoninol-octreotide (Compound 13) is a Somatostatin analog. Des-threoninol-octreotide inhibits cloned somatostatin receptors with IC50 values of 13.62 nM, 10.63 nM, 10.95 nM for mSSTR2b, rSSTR5 and hSSTR5, respectively.
    Des-threoninol-octreotide
  • HY-P11473
    NANP6 peptide 98%
    NANP6 peptide is an antigen peptide. NANP6 peptide can be used for the detection of anti-NANP in ELISA. NANP6 antibody titer strongly correlated with protection from liver infection.
    NANP6 peptide
  • HY-P11487
    UTG-4 98%
    UTG-4 is a GLP-1R, GIPR, and GCGR agonist with EC50 values of 126.3 pM, 29.2 pM, and 250.2 pM, respectively. UTG-4 binds to HSA (Kd = 14.6 μM). UTG-4 effectively alleviates endothelial-mesenchymal transition. UTG-4 promotes weight loss, inhibits food intake, improves glucose tolerance, and has a significant anti-atherosclerotic effect.
    UTG-4
  • HY-P11552
    (Asp-Ser-Ser)6 929906-72-9 98%
    (Asp-Ser-Ser)6 ((DSS)6) is an artificially designed bone-targeting peptide. (Asp-Ser-Ser)6 is used as a ligand to modify apoptotic extracellular vesicles (ApoEVs) in order to enhance the bone targeting and efficacy of ApoEVs in the treatment of osteoporosis. (Asp-Ser-Ser)6 can be used for research on osteoporosis.
    (Asp-Ser-Ser)6
  • HY-P11584
    KBP-066A 98%
    KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity.
    KBP-066A
  • HY-P11586
    San45 98%
    San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity.
    San45
  • HY-P11587
    BGM1812
    BGM1812 is a dual agonist of amylin (hAMY3R) (EC50 = 0.627 nM) and CGRP Receptor (hCTR) (EC50 = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity.
    BGM1812
  • HY-P11588
    KBP-042 98%
    KBP-042 is an orally active amylin receptor activator, a calcitonin receptor activator. KBP-042 induces sustained weight loss, reduces adipose tissue mass, lowers hepatic lipid deposition, increases plasma adiponectin, decreases plasma leptin, and reduces plasma glucose-dependent insulinotropic peptide levels. KBP-042 can be used for the research of obesity and insulin resistance.
    KBP-042
  • HY-P11589
    PIISVYWK 2016043-80-2 98%
    PIISVYWK is an orally active PPARγ Inhibitor, heme oxygenase-1 Activator, and Nrf2 Activator. PIISVYWK mediates activity via the HO-1/Nrf2 pathway, ameliorates oxidative stress, reduces inflammation, and mediates anti-obesity activity. PIISVYWK can be used for the research of obesity.
    PIISVYWK
  • HY-P11608
    FSVVPSPK 2016043-82-4 98%
    FSVVPSPK is an orally active peptide. FSVVPSPK exerts significant anti-adipogenic, antioxidant and anti-inflammatory effects in vitro and in vivo, mainly through activating the HO-1/Nrf2 pathway. FSVVPSPK can be used in research related to obesity and metabolic disorders.
    FSVVPSPK
  • HY-P11609
    TGFβ1-IN-4 98%
    TGFβ1-IN-4 is a TGF-β1 inhibitor. TGFβ1-IN-4 inhibits myofibroblast activation and epithelial-mesenchymal transition in vitro. TGFβ1-IN-4 alleviates renal fibrosis in a mouse model of renal fibrosis. TGFβ1-IN-4 can be used for research on fibrotic diseases such as renal fibrosis.
    TGFβ1-IN-4
  • HY-P1160A
    Bay 55-9837 TFA 98%
    Bay 55-9837 TFA is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes.
    Bay 55-9837 TFA
  • HY-P11610
    KBP-089 1776112-67-4
    KBP-089 is a dual Amylin and Calcitonin Receptor agonist. KBP-089 reduces body weight, decreases adipose tissue mass and improves glucose tolerance in obese rats. KBP-089 also eliminates lipid accumulation in the liver and muscle, and ameliorates glycemic homeostasis and insulin sensitivity. KBP-089 is applicable to the research of diseases such as obesity and type 2 diabetes.
    KBP-089
  • HY-P11612
    ATS-9R 98%
    ATS-9R is a peptide consisting of an adipocyte-targeting sequence and D-form 9-arginine. ATS-9R selectively transfects mature adipocytes by binding to prohibitin. ATS-9R allows an adipocyte-targeted gene delivery in vitro and in vivo. ATS-9R can be used for the development of an adipocyte-targeted gene carrier. ATS-9R can be used for the study of obesity as well as obesity-induced metabolic syndromes.
    ATS-9R
  • HY-P11626
    Cyclo(Ala-Hyp) 67943-21-9
    Cyclo(Ala-Hyp) is an orally effective collagen-derived hydroxyproline-containing cyclic dipeptide that can be isolated from the culture supernatant of Lactobacillus plantarum. Cyclo(Ala-Hyp) has an AUC0-6h of 2.350 μg/mL·h, significantly higher than traditional collagen oligopeptides. Cyclo(Ala-Hyp) can be used in research related to liver and kidney function protection, skin care, and joint health.
    Cyclo(Ala-Hyp)
  • HY-P11629
    KBP-336
    KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis.
    KBP-336
  • HY-P11646
    Brazzein 178359-31-4 98%
    Brazzein is a functional sweetener with antioxidant, anti-inflammatory, and anti-allergic activities.
    Brazzein inhibits COX-2 with an IC50 of 12.62 μM. Brazzein exhibits strong antioxidant effects, showing ABTS radical scavenging activity (IC50 = 12.55 μM). Brazzein shows no antibacterial or antifungal activity. Brazzein can be used for the research of obesity, metabolic disorder, inflammation.
    Brazzein
  • HY-P11664
    Anvoglutide 3091730-40-1
    Anvoglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with antidiabetic and obesity effects.
    Anvoglutide
  • HY-P11665
    Batelintide 3034703-92-6
    Batelintide is a dual amylin/calcitonin receptor agonist with antidiabetic effects.
    Batelintide
Cat. No. Product Name / Synonyms Application Reactivity